Author

Victoria E. H. Wang

Observed names: V.E.H. Wang, Victoria E. Wang, Victoria Elizabeth Wang, Victoria Wang

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Observed institutions: National Institutes of Health, Harvard University, University of California, San Francisco, University of California San Francisco Medical Center, National Institute of Allergy and Infectious Diseases, National Cancer Institute, Center for Cancer Research, UCSF Helen Diller Family Comprehensive Cancer Center, Massachusetts Institute of Technology

ORCID: 0000-0001-9052-3531

Observed ORCID: 0000-0001-9052-3531

OpenAlex ID: A5062376578

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

2017 · Collin M Blakely, Thomas B K Watkins, et al. · Nature Genetics · 571

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

2018 · Khyati N. Shah, Roma Bhatt, et al. · Nature Medicine · 283

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

2013 · Mark N. Polizzotto, Thomas S. Uldrick, et al. · Blood · 158

The Octamer Binding Transcription Factor Oct-1 Is a Stress Sensor

2005 · Dean Tantin, Caroline Schild-Poulter, et al. · Cancer Research · 112

Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity

2009 · Arvind Shakya, Robert Cooksey, et al. · Nature Cell Biology · 96

Embryonic Lethality, Decreased Erythropoiesis, and Defective Octamer-Dependent Promoter Activation in Oct-1-Deficient Mice

2004 · Victoria E. H. Wang, Tara Schmidt, et al. · Molecular and Cellular Biology · 83

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

2017 · Victoria E. Wang, Anatoly Urisman, et al. · Journal for ImmunoTherapy of Cancer · 68

PDF

Genetic Organization and Hypoxic Activation of the Kaposi's Sarcoma-Associated Herpesvirus ORF34-37 Gene Cluster

2006 · Muzammel Haque, Victoria Wang, et al. · Journal of Virology · 67

Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation

2019 · Victoria E. Wang, Jenny Y. Xue, et al. · Clinical Cancer Research · 55

Herpes simplex virus infections are arrested in Oct-1-deficient cells

2004 · Mauricio L. Nogueira, Victoria E. H. Wang, et al. · Proceedings of the National Academy of Sciences · 50

68 Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18 F-FDG

2024 · Brad Kline, Surekha Yadav, et al. · Journal of Nuclear Medicine · 47

PDF

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases

2017 · Victoria E. Wang, Lauren Young, et al. · The Oncologist · 43

PDF

New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints

2016 · Victoria E. Wang, Jennifer R. Grandis, et al. · Clinical Cancer Research · 37

B cell development and immunoglobulin transcription in Oct-1-deficient mice

2004 · Victoria E. H. Wang, Dean Tantin, et al. · Proceedings of the National Academy of Sciences · 37

A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay

2015 · Mark Jesus M. Magbanua, Michael Pugia, et al. · PLoS ONE · 29

PDF

Evaluation of a National Comprehensive Cancer Network Guidelines–Based Decision Support Tool in Patients With Non–Small Cell Lung Cancer

2020 · Susan Y. Wu, Ann A. Lazar, et al. · JAMA Network Open · 17

PDF

Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).

2017 · Young Kwang Chae, Keerthi Tamragouri, et al. · Journal of Clinical Oncology · 16

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

2021 · Victoria E. Wang, Bradley W. Blaser, et al. · Blood Cancer Discovery · 11

PDF

CD74 - ROS1 Fusion in NSCLC Detected by Hybrid Capture–Based Tissue Genomic Profiling and ctDNA Assays

2017 · Victoria Wang, Trever Bivona, et al. · Journal of Thoracic Oncology · 6

The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.

2026 · Hans Gelderblom, Victoria Wang, et al. · Journal of Clinical Oncology · 5

Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns?

2023 · Victoria E. Wang, Justin F. Gainor · JAMA Oncology · 3

Off-label targeted therapy (TT) use in recurrent/metastatic NSCLC.

2021 · Victoria Wang, Chenming Cui, et al. · Journal of Clinical Oncology · 2

Analysis of Multiplexed Single Cell RNA Sequencing Clinical Correlative Data in AML Reveals Biomarkers of Resistance

2020 · Charalambos Andreadis, Tommy Jiang, et al. · Blood · 2

Abstract 2902: Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC

2019 · Khyati N. Shah, Roma Bhatt, et al. · Cancer Research · 2

Abstract 3182: Cytoskeletal modulation results in increased tumor survival and drug resistance through attenuation of p53 dependent apoptosis

2017 · Victoria E. Wang, John Doench, et al. · Cancer Research · 2

Works count: 95

Citation count: 1,810

H-index: 16

I10-index: 18